| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A420 | Nofazinlimab Featured | Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research. |
|
| A421 | Cetrelimab Featured | Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo. |
|
| A422 | Budigalimab Featured | Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function. |
|
| A423 | Ezabenlimab Featured | Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo. |
|
| A424 | Serplulimab Featured | Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer. |
|
| A425 | Penpulimab Featured | Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities. |
|
| A426 | Balstilimab Featured | Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1. |
|
| A427 | UCB patent anti-PD-1 Featured |
|
|
| A428 | Anti-PDGFB Antibody (MOR-8457) Featured |
|
|
| A429 | Thrombogenics patent anti-PDGF-C Featured |
|
|
| A430 | Olaratumab Featured | Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity. |
|
| A431 | Tovetumab Featured | Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). |
|
| A432 | Anti-PDGFRB/CD140b Antibody (IMC-2C5) Featured |
|
|
| A433 | Novo Nordisk patent anti-PGLYRP1 Featured |
|
|
| A434 | Bavituximab Featured | Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer. |
|
| A435 | ATH3G10 Featured |
|
|
| A436 | Diaccurate patent anti-sPLA2-GIB Featured |
|
|
| A437 | ATN-658 Featured |
|
|
| A438 | Genentech anti-PMEL17 Featured |
|
|
| A439 | Novartis patent anti-PMEL17 Featured |
|
|
| A440 | Genentech patent anti-Polyubiquitin Featured |
|
|
| A441 | Eureka patent anti-PRAME Featured |
|
|
| A442 | BAY-1158061 Featured |
|
|
| A443 | Rolinsatamab Featured | Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). |
|
| A444 | Forerunner patent anti-Prominin-1 Featured |
|
|
| A445 | AGS-1C4D4 Featured |
|
|
| A446 | Inclacumab Featured | Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion. |
|
| A447 | Neihulizumab Featured | Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research. |
|
| A448 | AG02-ADC Featured |
|
|
| DC65219 | ACT-777991 Featured | ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11. |
|
